Development of an ELISA for the quantification of mycolactone, the cytotoxic macrolide toxin of Mycobacterium ulcerans

PLoS Negl Trop Dis. 2020 Jun 26;14(6):e0008357. doi: 10.1371/journal.pntd.0008357. eCollection 2020 Jun.

Abstract

Mycolactones, macrolide cytotoxins, are key virulence factors of Mycobacterium ulcerans, the etiological agent of the chronic necrotizing skin disease Buruli ulcer. There is urgent need for a simple point-of-care laboratory test for Buruli ulcer and mycolactone represents a promising target for the development of an immunological assay. However, for a long time, all efforts to generate mycolactone-specific antibodies have failed. By using a protein conjugate of a truncated non-toxic synthetic mycolactone derivative, we recently described generation of a set of mycolactone-specific monoclonal antibodies. Using the first mycolactone-specific monoclonal antibodies that we have described before, we were able to develop an antigen competition assay that detects mycolactones. By the systematic selection of a capturing antibody and a reporter molecule, and the optimization of assay conditions, we developed an ELISA that detects common natural variants of mycolactone with a limit of detection in the low nanomolar range. The mycolactone-specific ELISA described here will be a very useful tool for research on the biology of this macrolide toxin. After conversion into a simple point-of-care test format, the competition assay may have great potential as laboratory assay for both the diagnosis of Buruli ulcer and for the monitoring of treatment efficacy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal
  • Buruli Ulcer / diagnosis
  • Buruli Ulcer / microbiology
  • Disease Models, Animal
  • Enzyme-Linked Immunosorbent Assay / methods*
  • Humans
  • Macrolides / chemistry
  • Macrolides / immunology*
  • Macrolides / isolation & purification*
  • Mice
  • Mice, Inbred BALB C
  • Molecular Diagnostic Techniques / methods
  • Mycobacterium ulcerans / isolation & purification
  • Mycobacterium ulcerans / metabolism*
  • Sensitivity and Specificity

Substances

  • Antibodies, Monoclonal
  • Macrolides
  • mycolactone

Grants and funding

The project was supported by the Medicor Foundation (https://www.medicor.li/ GP) and the Foundation for Innovative New Diagnostics (https://www.finddx.org/ GP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.